CJC-1295 DAC Structure and Sequence:
- Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 (Drug Affinity Complex) DAC
- Molecular Formula: C165H269N47O46
- Molar Mass: 3647.15
- CAS Number: 863288-34-0
CJC-1295 DAC (Drug Affinity Complex), also known as CJC-1295, is a synthetic GHRH (Growth Hormone Releasing Hormone) that is long acting. After administration, it covalently binds to albumin naturally created by the human body, causing it to extend its duration of action. This means it has a far longer half life (between six and eight days) than other peptides like Sermorelin and Mod GRF 1-29 . Sermorelin and Modified GRF 1-29 have a half life of 5-10 minutes , and about 30 minutes , respectively. A shorter half life results in inefficiency because the peptide does not reach the pituitary within enough time for the peptide to become effectual. Unlike Mod GRF 1-29, CJC-1295 DAC is a drug affinity complex, where there is a lysine connection to maleimidoproprionic acid (MPA) .
In the average and healthy human body, growth hormones are kept in the pituitary gland. A GHRH, naturally occurring or synthetic, signals to the pituitary to release growth hormone. Most individuals, naturally, are able to create growth hormone in their pituitary gland. However, some can not release the necessary amount of growth hormone. GHRP increases the amount of growth hormone releasing cells. The quantity released by each cell is unaffected. CJC-1295 DAC, and other peptides like GHRP-6 and GHRP-2, have the possibility of assisting in the attainment of necessary growth hormone levels.
Clinical studies have shown that the administration of CJC-1295, which was developed by ConjuChem, in certain specific situations and intervals, may cause the achievement of normal body weight when GHRH levels are low, greater body weight, and an increase in total pituitary RNA and growth hormone. The last of which suggests that more growth hormone releasing cells were created . Other studies have provided evidence that one administration of CJC-1295 produced sustained elevations of serum growth hormone and insulin-like growth factor 1 levels in normal subjects for nearly fourteen days .
Studies have also shown no serious adverse reactions in the use of CJC-1295 . The most often occurring adverse reactions are injection site reactions, such as pain and swelling.
 Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Teichman, Sam L., et al., The Journal of Clinical Endocrinology & Metabolism 91(3):799 – 805
 Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. Frohman L.A., Clin Invest 78 (4): 906–913
 New potent hGH-RH analogues with increased resistance to enzymatic degradation". Izdebski, Jan, JJ Pept Sci. 8 (7): 285–287
 See Footnote 1.
 Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Alba, Maria, et al., Am J Physiol Endocrinol Metab 291: E1290 –E1294, 2006.
 See Footnote 1.
 See footnote 1.
All product information available on this website is for educational purposes only. This product is not a drug, food or cosmetic and should not be mislabeled, misbranded or misused as a drug, food or cosmetic. Licensed, qualified professionals in a laboratory setting should only use this product. This product is not for human consumption and bodily introduction of any kind is strictly forbidden. This product is a research chemical only.